- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering | 2 | GlobeNewswire (USA) | ||
| Di | Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share | 2 | Investing.com | ||
| Di | Taiwan's Jyong Biotech doubles in value on Nasdaq debut | 1 | Investing.com | ||
| Di | Urinary disease biotech Jyong Biotech prices US IPO at $7.50, the low end of the range | 1 | Renaissance Capital | ||
| Di | Jyong Biotech Prices 2.67M Share IPO at $7.50/sh | 2 | Investing.com | ||
| Di | Jyong Biotech Announces Pricing Of 2.67 Mln Shares IPO At $7.50/Shr | 1 | RTTNews | ||
| Di | Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering | 92 | GlobeNewswire (Europe) | New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative... ► Artikel lesen | |
| 12.06. | Jyong Biotech Ltd. - 8-A12B, Registration of securities | - | SEC Filings | ||
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 11.03. | Jyong Biotech Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 06.02. | Urinary disease biotech Jyong Biotech sets terms for $19 million US IPO | 1 | Renaissance Capital | ||
| 06.02. | Jyong Biotech Ltd. - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 27,830 | 0,00 % | Caris Life Sciences Prices IPO Of About 23.53 Mln Shares At $21.00/shr | WASHINGTON (dpa-AFX) - Caris Life Sciences (Caris) announced that it has priced its initial public offering of about 23.53 million shares of its common stock at a public offering price of $21.00... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,790 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| TAYSHA GENE THERAPIES | 2,570 | +0,78 % | Cantor Fitzgerald behält Kursziel von 13 US-Dollar für Taysha Gene Therapies bei | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Eli Lilly will Verve Therapeutics schlucken - 113 Prozent Aufschlag! | Der Pharma-Riese Eli Lilly bleibt seiner aktiven M&A-Strategie treu. Die Amerikaner wollen sich mit der Übernahme von Verve Therapeutics im Gene-Editing-Bereich verstärken. Eli Lilly lässt sich den... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,095 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| REGENCELL BIOSCIENCE | 63,35 | 0,00 % | Regencell Bioscience Holdings Ltd - 6-K, Report of foreign issuer | ||
| IMMUNOME | 8,830 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| LEXEO THERAPEUTICS | 4,240 | 0,00 % | Lexeo Therapeutics files to sell 41.63M shares of common stock for holders | ||
| ADMA BIOLOGICS | 18,135 | 0,00 % | ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? | ||
| NURIX THERAPEUTICS | 11,620 | +2,02 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,660 | 0,00 % | Arcutis Biotherapeutics, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 10,790 | 0,00 % | Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint | WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced... ► Artikel lesen | |
| TANGO THERAPEUTICS | 4,800 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| QIAGEN | 40,140 | -1,07 % | Verhaltene Kauflaune bei Aktie von Qiagen NV (40,695 €) | Die Wertschätzung für den Anteilsschein von Qiagen NV hat sich am Aktienmarkt heute kaum geändert. Der jüngste Kurs betrug 40,70 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 12,350 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen |
Das Unternehmen JYONG BIOTECH LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 8,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.